lntralytix
was founded in 1998 to address growing problems in the control and
treatment of disease-causing bacteria. These problems are presently
compounded by public and governmental reluctance to employ new and
potentially hazardous chemical agents or solutions born of recombinant
technology. Intralytix is using its core bacteriophage technology to
develop novel natural products for use in food processing, environmental
clean-up, sanitation, consumer products, and problems of antibiotic
resistance in human therapy.
Intralytix
benefits from the strength, diversity, and balance between science and
business of its founders. The technical team includes J. Glenn Morris,
M.D., an expert in infectious disease, epidemiology, and food
microbiology who was instrumental in writing the new USDA regulations on
microbial safety in meat processing, and Alexander Sulakvelidze, Ph.D.,
an expert in molecular microbiology and bacteriophage technology.
The Intralytix CEO, John D. Vazzana, has over 34 years of business
experience, and he has been instrumental in transforming several
start-up or small companies into profitable, publicly-traded
corporations. This core team is
rounded out by co-founders who are seasoned experts in technology
development, business, finance, regulatory affairs, intellectual
property, and legal aspects of developing technology-based businesses,
including: Patrick Hervy, chairman of MDBio and Paragon Biotech, and
former CEO of U.S. operations for Thomsen CGR; John Woloszyn, Esq., a
partner in a major international law firm and chairman of Lombard
Securities who has twenty years of experience working with early-stage
technology-based companies; Dr. Torrey C. Brown, M.D., the former
Maryland State Secretary of Natural Resources, with extensive business
and corporate development experience; Nina Siegler, M.B.A., C.F.A., a former Wall
Street biotechnology securities analyst and director of The Johns
Hopkins University Office of Technology Transfer; and Gary Pasternack,
M.D., Ph.D., a scientist with extensive translational and biotechnology
experience who directs the Division of Molecular Pathology at Johns
Hopkins.
